Table 1.
Change in Height (cm) from Baseline to 24 and 48 months*
| Stratifying Variable | Strata | N | Change in Height from Baseline to 24 months | Change in Height from Baseline to 48 months | ||||
|---|---|---|---|---|---|---|---|---|
| ICS mean (95% CI) | Placebo mean (95% CI) | ICS vs Placebo (95% CI) | ICS mean (95% CI) | Placebo mean (95% CI) | ICS vs Placebo (95% CI) | |||
| Overall Cohort | 204 | 12.6 (12.2, 13.0) | 13.5 (13.2, 13.9) | −0.9 (−1.4, −0.4) ‡ | 25.7 (25.0, 26.3) | 25.9 (25.3, 26.5) | −0.2 (−1.1, 0.6) | |
| Age | 2 yrs | 105 | 13.4 (12.8, 13.9) | 14.4 (13.9, 15.0) | −1.1 (−1.8, −0.3) ‡ | 26.6 (25.8, 27.4) | 27.5 (26.7, 28.3) | −0.8 (−1.9, 0.3) |
| 3 yrs | 99 | 11.9 (11.3, 12.4) | 12.7 (12.2, 13.1) | −0.8 (−1.5, −0.1) + | 24.7 (23.8, 25.7) | 24.4 (23.5, 25.2) | 0.4 (−0.9, 1.6) | |
| Baseline Weight | < 15 kg | 104 | 12.3 (11.8, 12.8) | 13.2 (12.7, 13.7) | −1.0 (−1.7, −0.3) ‡ | 24.9 (24.2, 25.7) | 25.4 (24.6, 26.3) | −0.5 (−1.6, 0.6) |
| ≥ 15 kg | 100 | 13.0 (12.3, 13.6) | 13.8 (13.4, 14.3) | −0.9 (−1.6, −0.1) + | 26.4 (25.4, 27.4) | 26.4 (25.6, 27.2) | 0.0 (−1.1, 1.2) | |
| Gender | Female | 124 | 12.7 (12.1, 13.3) | 13.6 (13.1, 14.1) | −0.9 (−1.7, −0.1) + | 25.9 (24.9, 27.0) | 26.1 (25.1, 27.0) | −0.1 (−1.5, 1.2) |
| Male | 80 | 12.5 (12.0, 13.0) | 13.4 (13.0, 13.9) | −0.9 (−1.6, −0.2) ‡ | 25.4 (24.7, 26.1) | 25.8 (25.1, 26.4) | −0.3 (−1.3, 0.6) | |
| Race | Caucasian | 118 | 12.3 (11.7, 12.8) | 13.3 (12.9, 13.7) | −1.0 (−1.7, −0.4) ‡ | 25.7 (24.8, 26.5) | 26.0 (25.2, 26.7) | −0.3 (−1.3, 0.8) |
| non-Caucasian | 86 | 13.0 (12.4, 13.5) | 13.7 (13.2, 14.3) | −0.8 (−1.6, 0.0) | 25.7 (24.8, 26.6) | 25.9 (25.0, 26.8) | −0.2 (−1.4, 1.1) | |
| Age 2 yrs: Baseline Weight | < 15 kg | 70 | 12.9 (12.4, 13.5) | 14.2 (13.6, 14.8) | −1.3 (−2.1, −0.5) ‡ | 25.7 (25.0, 26.5) | 27.3 (26.4, 28.3) | −1.6 (−2.8, −0.4) ‡ |
| ≥ 15 kg | 35 | 13.8 (12.8, 14.8) | 14.6 (13.8, 15.4) | −0.8 (−2.1, 0.4) | 27.5 (26.2, 28.9) | 27.6 (26.4, 28.8) | −0.1 (−1.9, 1.7) | |
| Age 3 yrs: Baseline Weight | < 15 kg | 34 | 11.6 (10.8, 12.5) | 12.3 (11.5, 13.0) | −0.6 (−1.7, 0.5) | 24.1 (22.9, 25.4) | 23.5 (22.2, 24.9) | 0.6 (−1.3, 2.4) |
| ≥ 15 kg | 65 | 12.1 (11.3, 12.9) | 13.0 (12.6, 13.5) | −0.9 (−1.8, 0.0) + | 25.3 (24.0, 26.6) | 25.2 (24.2, 26.1) | 0.1 (−1.4, 1.7) | |
*
The linear mixed-effects regression model was adjusted for baseline covariates including clinical center, gender, race, history of eczema, during of percent blood eosinophils, aeroallergen skin test positivity, age, weight and height.
+
Difference between ICS and Placebo significant at p<0.05
‡
Difference between ICS and Placebo significant at p<0.01